P&K Skin Research Center Co. Ltd (347740) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of P&K Skin Research Center Co. Ltd stock KRW 3,443, price KRW 1,801, upside +91.2%, quality 70 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 1,515 KRW – 7,008 KRW · fair‑value band 2,233 KRW – 4,476 KRW · the 1,801 KRW price screens below the 3,443 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow P&K Skin Research Center Co. in your weekly email
Every Wednesday you see whether P&K Skin Research Center Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs.
Show moreShow less
The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vitro tests. It also manufactures and sells raw pharmaceutical and cosmetic materials, and raw materials for health foods. The company was founded in 2010 and is headquartered in Seoul, South Korea.
P&K Skin Research Center Co., Ltd. is a subsidiary of Daebongls. Co.,Ltd.
Stock analysis
P&K Skin Research Center Co. Ltd (347740) currently trades at 1,801 KRW, while our model-based Fair Value estimate is 3,443 KRW, implying the stock looks roughly 48% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 3,877 KRW per share, and 19 of the 26 models we run sit above the 1,801 KRW price.
Bear case: the Dividend Discount group reads lowest at 535.69 KRW, and 7 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 2,233 KRW (bear) to 4,476 KRW (bull), the price of 1,801 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
P&K Skin Research Center Co. Ltd reported revenue of 22.8B KRW in FY2025 versus 17.5B KRW in FY2021, a compound +6.8%/yr. Reported net income was 4.7B KRW in FY2025, compounding −10.5%/yr from FY2021.
Key figures
Market cap 52.0B KRW (≈ $38.5M) Micro · P/E ratio 14.0 · P/S ratio 2.20 · EPS (TTM) 129.23 KRW · Dividend yield 2.8% · Net margin 15.8% · Return on equity 4.5% · Return on assets (EBIT) 5.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 91%, 347740 screens cheaper than that median.
Fair Value models
Bear2,233 KRWFair Value 3,443 KRWBull4,476 KRW
Price 1,801 KRW · Upside +91.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (67.94 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+27.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.5%
Dividend (yield on the price)2.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.49% → 17%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−31.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −32.5% a year for the price.
Compare P&K Skin Research Center Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+91.2% · Top 25%
Profitability
Return on equity (12 months)4.5% · Above median
Return on assets5.4% · Above median
Net margin (12 months)15.8% · Top 25%
Operating margin (12 months)22.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)20.1% · Top 25%
Dividend yield (12 months)2.8% · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "P&K Skin Research Center Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/347740
Frequently asked questions
Is P&K Skin Research Center Co. Ltd (347740) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 3,443 KRW versus a price of 1,801 KRW, about +91% upside (undervalued).
What is the fair value of 347740?
Our model-based fair value for P&K Skin Research Center Co. Ltd is 3,443 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 1,801 KRW.
What is the quality score of 347740?
P&K Skin Research Center Co. Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for P&K Skin Research Center Co. Ltd (347740)?
Our model-based price target is the fair value of 3,443 KRW (as of Nov 3, 2026) from 26 valuation models. Cautious scenario 2,233 KRW, optimistic scenario 4,476 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the P&K Skin Research Center Co. Ltd stock forecast for 2026?
Our models put fair value at 3,443 KRW, about +91% upside versus a price of 1,801 KRW (undervalued). Cautious scenario 2,233 KRW, optimistic scenario 4,476 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of P&K Skin Research Center Co. Ltd (347740)?
P&K Skin Research Center Co. Ltd reported trailing-twelve-month revenue of about 23.7B KRW (latest available figure, as of Nov 3, 2026).
Does P&K Skin Research Center Co. Ltd pay a dividend?
P&K Skin Research Center Co. Ltd currently shows a dividend yield of 2.78% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of P&K Skin Research Center Co. Ltd (347740) and when is the ex-dividend date?
P&K Skin Research Center Co. Ltd pays a dividend of 50.00 KRW per share a year, a dividend yield of 2.8%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2021. The payout ratio is 38.7% of earnings. Free cash flow covers the dividend 3.58 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into P&K Skin Research Center Co. Ltd (347740)?
For today's price to be fair in a discounted-cash-flow model, P&K Skin Research Center Co. Ltd would have to grow free cash flow by -31.1 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.2 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 347740 use?
Our models discount P&K Skin Research Center Co. Ltd at 9.7 %: a base by market capitalisation (nano), damped by beta 0.83, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For P&K Skin Research Center Co. Ltd that is -31.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has P&K Skin Research Center Co. Ltd (347740) delivered so far?
Over the past 5 years revenue at P&K Skin Research Center Co. Ltd grew +9.2 % a year. The price currently implies free-cash-flow growth of -31.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of P&K Skin Research Center Co. Ltd (347740) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into P&K Skin Research Center Co. Ltd (-31.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of P&K Skin Research Center Co. Ltd (347740)?
The free-cash-flow yield on the price is 9.95 %: that much free cash flow P&K Skin Research Center Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of P&K Skin Research Center Co. Ltd (347740)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For P&K Skin Research Center Co. Ltd it is 3,443 KRW per share (as of Nov 3, 2026), against a price of 1,801 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is P&K Skin Research Center Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 347740 trades below its calculated fair value: price 1,801 KRW, fair value 3,443 KRW, a gap of about +91% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 347740?
No. The price is what the market pays today (1,801 KRW); the fair value is what the company's own numbers justify (3,443 KRW). For P&K Skin Research Center Co. Ltd the two are 1,642 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is P&K Skin Research Center Co. Ltd worth?
The market values P&K Skin Research Center Co. Ltd at about 52.0B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 1,801 KRW; our models calculate a fair value of 3,443 KRW per share.
What do the bullish and bearish scenarios say about 347740?
Our models span a range for P&K Skin Research Center Co. Ltd: cautious scenario 2,233 KRW, base 3,443 KRW, optimistic 4,476 KRW per share (as of Nov 3, 2026, price 1,801 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 347740?
P&K Skin Research Center Co. Ltd trades at a price-to-earnings ratio of 14.0 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3,443 KRW is built from several models across several years. Other multiples: P/B 0.7, P/S 2.2, EV/EBITDA 8.4.
How solid is the balance sheet of P&K Skin Research Center Co. Ltd (347740)?
Balance-sheet figures for P&K Skin Research Center Co. Ltd (as of Nov 3, 2026): return on equity 4.5%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 347740 from its 52-week high?
P&K Skin Research Center Co. Ltd trades at 1,801 KRW, about 33% below its 52-week high of 2,689 KRW and 19% above the low of 1,515 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3,443 KRW is for.
Which stocks are comparable to P&K Skin Research Center Co. Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is P&K Skin Research Center Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 1,801 KRW, calculated fair value 3,443 KRW (+91%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 347740 calculated?
We run P&K Skin Research Center Co. Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 3,443 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. P&K Skin Research Center Co. Ltd currently trades 48% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of P&K Skin Research Center Co. Ltd (347740)?
The closing price on Nov 6, 2026 was 1,801 KRW. Our model-based fair value is 3,443 KRW, about +91% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with P&K Skin Research Center Co. Ltd right now?
The price is below even our cautious bear case (2,233 KRW). The market is more pessimistic than our downside scenario. Solid quality (70/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (2,233 KRW to 4,476 KRW) leaves room in how you read the outcome.
Key figures of P&K Skin Research Center Co. Ltd
How large is the market capitalisation of P&K Skin Research Center Co. Ltd (347740)?
The market capitalisation of P&K Skin Research Center Co. Ltd is 52.0B KRW (≈ $38.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of P&K Skin Research Center Co. Ltd (347740)?
The price-to-sales ratio of P&K Skin Research Center Co. Ltd is 2.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of P&K Skin Research Center Co. Ltd (347740)?
Earnings per share at P&K Skin Research Center Co. Ltd are 129.23 KRW (price ÷ EPS = P/E 14.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of P&K Skin Research Center Co. Ltd (347740)?
The dividend yield of P&K Skin Research Center Co. Ltd is 2.8% (payout 38.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of P&K Skin Research Center Co. Ltd (347740)?
The net margin of P&K Skin Research Center Co. Ltd is 15.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of P&K Skin Research Center Co. Ltd (347740)?
The return on equity (ROE) of P&K Skin Research Center Co. Ltd is 4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of P&K Skin Research Center Co. Ltd (347740)?
On an EBIT basis the return on assets of P&K Skin Research Center Co. Ltd is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of P&K Skin Research Center Co. Ltd (347740)?
The operating margin of P&K Skin Research Center Co. Ltd is 22.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at P&K Skin Research Center Co. Ltd (347740)?
Revenue at P&K Skin Research Center Co. Ltd is growing +20.1% versus a year earlier (3y avg +8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at P&K Skin Research Center Co. Ltd (347740)?
Earnings per share at P&K Skin Research Center Co. Ltd are growing −5.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch P&K Skin Research Center Co. Ltd in the live analysis
One click puts P&K Skin Research Center Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026